TD Cowen Reiterates Buy Rating on Jade Biosciences (JBIO): "potential best-in-class"

TD Cowen analyst Tyler Van Buren reiterated a Buy rating on Jade Biosciences (NASDAQ: JBIO)

The analyst commented, "JADE101 is designed to completely suppress APRIL and maximize efficacy of the anti-APRIL class for IgAN. The Phase I data in Q2 will be biomarker-rich to inform whether '101 can support Q8W+ dosing and deeper, more durable IgA reductions than sibe, which correlate to proteinuria reduction in IgAN. We believe a >50% IgA reduction for over 55-days would suggest a best-in-class candidate... JADE101 is a potential best-in-class pure anti-APRIL mAb designed to completely suppress APRIL throughout its dosing interval. As detailed in the preclinical data at ERA, JADE101 binds a novel APRIL epitope to mitigate the TMDD effect, supporting its ~3.7x longer half-life than Otsuka's sibe."

For an analyst ratings summary and ratings history on Jade Biosciences click here. For more ratings news on Jade Biosciences click here.

Shares of Jade Biosciences closed at $14.05 yesterday.

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• RBC Capital on Veeva Systems (VEEV) Amid After Hours Selloff on Earnings: 'we are surprised to see shares trade down'
• Jade Biosciences announces underwritten public offering of common stock